Mark A. Socinski, MD, AdventHealth Cancer Institute
Articles
Challenges for TRK Fusion–Targeting Agents
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Acquired Resistance in TRK Fusion-Positive Cancers
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Approaching Treatment for TRK Fusion–Positive Cancers
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
TRK Inhibitor in GI Cancers: Adverse Effect Profile
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Early Development of TRK Inhibitors
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Advice for Interpreting NGS Reports
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Driver Mutations in NTRK Fusion-Positive Cancers
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Genomic Testing for NTRK Fusions in Lung and GI Cancers
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Approaching Genomic Testing for NTRK Fusions
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Using Molecular Testing in GI Cancers
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Evolution of NGS Testing in Lung Cancers
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Variants of NTRK Fusions in Solid Tumors
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
John L. Marshall, MD, MedStar Georgetown University Hospital;Tanios S. Bekaii-Saab, MD, Mayo Clinic;Shubham Pant, MD, MD Anderson Cancer Center;Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center;Luis E. Raez, MD, Memorial Healthcare System;Mark A. Socinski, MD, AdventHealth Cancer Institute
May 21st 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
